Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press1712110.36691/RJA17121LFUBUKReviewsНаучные обзорыReview ArticleAllergen-specific immunotherapy for atopic dermatitis: current status, problems and prospectsАллергенспецифическая иммунотерапия при атопическом дерматите: современное состояние проблемы и перспективыhttps://orcid.org/0009-0009-6943-947XIuzhaninovaValeriia S.ЮжаниноваВалерия Сергеевна
Russian Federation
qwwvl1@yandex.ruhttps://orcid.org/0000-0002-4609-25919567-1894ElisyutinaOlga G.ЕлисютинаОльга Гурьевна
Russian Federation

MD, Dr. Sci. (Medicine)

д-р мед. наук

el-olga@yandex.ruhttps://orcid.org/0000-0003-1302-41784874-8100SmolnikovEvgeniy V.СмольниковЕвгений Валентинович
Russian Federation

MD

qweril2010@yandex.ruhttps://orcid.org/0000-0003-3358-50875012-7242FedenkoElena S.ФеденкоЕлена Сергеевна
Russian Federation

MD, Dr. Sci. (Medicine), Professor

д-р мед. наук, профессор

efedks@gmail.comhttps://orcid.org/0000-0002-3556-969X6715-5650IlyinaNatalya I.ИльинаНаталья Ивановна
Russian Federation

MD, Dr. Sci. (Medicine), Professor

д-р мед. наук, профессор

instimmun@yandex.ruhttps://orcid.org/0009-0005-2103-6234KleinerDina V.КлейнерДина Владимировна
Russian Federation

MD, Cand. Sci. (Medicine)

канд. мед. наук

kleiner.dina@gmail.comNational Research Center — Institute of Immunology Federal Medical-Biological AgencyГосударственный научный центр «Институт иммунологии»RUDN UniversityРоссийский университет дружбы народов имени Патриса ЛумумбыThe Russian National Research Medical University named after N.I. PirogovРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаStallergenes VostokСталлержен Восток06052026250520262322212282003202601052026Copyright ©; 2026, ABV-pressCopyright ©; 2026, АБВ-пресс2026ABV-pressАБВ-прессhttps://rusalljournal.ru/raj/about/submissions#copyrightNoticehttps://rusalljournal.ru/raj/article/view/17121

Atopic dermatitis is one of the most common skin diseases (accounting for 20 to 40 %) and occurs in individuals of both sexes and across different age groups. The disease can significantly reduce quality of life, including serving as a cause of social maladaptation; therefore, the issue of studying effective methods for the treatment of atopic dermatitis remains relevant, aimed at minimizing its manifestations and prolonging periods of remission. The key components of the pathogenesis of atopic dermatitis are impairment of the skin barrier function, chronic T2-inflammation, and the development of immunoglobulin E specific sensitization to allergens. Along with allergic rhinitis and bronchial asthma, atopic dermatitis belongs to T2-associated diseases, for which one of the treatment options is allergen-specific immunotherapy. This method has proven successful in the treatment of atopic diseases and, due to its disease-modifying effect, the issue of its efficacy and safety in patients with atopic dermatitis has been actively studied in recent years.

This review summarizes current data on the use of allergen-specific immunotherapy with house dust mite allergens in patients with atopic dermatitis and presents a case report illustrating the successful use of allergen-specific immunotherapy with house dust mites allergen in a patient with atopic comorbidities.

Атопический дерматит — одно из наиболее распространенных заболеваний (20–40 % случаев в структуре кожной патологии). Оно встречается во всех странах, у лиц обоего пола и в разных возрастных группах, существенно снижает качество жизни, может стать причиной социальной дезадаптации. В связи с этим актуален поиск эффективных методов лечения, которые помогут минимизировать проявления атопического дерматита и продлить периоды ремиссии. Ведущими звеньями патогенеза являются нарушение функции кожного барьера, хроническое Т2-воспаление и развитие сенсибилизации к аллергенам, опосредованной иммуноглобулином Е. Наряду с аллергическим ринитом и бронхиальной астмой атопический дерматит относится к Т2-ассоциированным заболеваниям, одной из опций лечения которых является аллергенспецифическая иммунотерапия. Данный метод успешно зарекомендовал себя в лечении аллергического ринита, бронхиальной астмы, инсектной и пищевой аллергии, и в последнее время активно изучаются его эффективность и безопасность при атопическом дерматите.

В обзоре обобщены современные данные о применении аллергенспецифической иммунотерапии у больных атопическим дерматитом, представлен клинический случай успешной аллергенспецифической иммунотерапии экстрактами аллергенов клещей домашней пыли у пациента с сопутствующими атопическими заболеваниями.

atopic dermatitisT2-inflammationsensitizationallergen-specific immunotherapyhouse dust mite allergensатопический дерматитТ2-воспалениесенсибилизацияаллергенспецифическая иммунотерапияаллергены клещей домашней пылиАтопический дерматит. Клинические рекомендации. Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России, Общероссийская общественная организация «Российское общество дерматовенерологов и косметологов», Общероссийская общественная организация «Национальный альянс дерматовенерологов и косметологов». 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/265_3 Дата обращения: 27.01.2026.Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2020;184(2):304–309. doi: 10.1111/bjd.19580 EDN: RDYCJDShin YH, Hwang J, Kwon R, et al. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Allergy. 2023;78(8):2232–2254. doi: 10.1111/all.15807 EDN: PNFVLSBogacz-Piaseczyńska A, Bożek A. Allergen immunotherapy in atopic dermatitis. Alergologia Polska — Polish Journal of Allergology. 2024;11(3):257–263. doi: 10.5114/pja.2024.142500 EDN: CNQXDOGuttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583–596. doi: 10.1016/S0140-6736(24)02519-4 EDN: HBAMDWPessina B, Giovannini M, Mori F, et al. Is there room for allergen immunotherapy for the treatment of atopic dermatitis in the precision medicine era? Front Pediatr. 2022;10:1050560. doi: 10.3389/fped.2022.1050560 EDN: RHATFNBai R, Zheng Y, Dai X. Atopic dermatitis: diagnosis, molecular pathogenesis, and therapeutics. Mol Biomed. 2025;6(1):71. doi: 10.1186/s43556-025-00313-3 EDN: ZWURNCPark CO, Kim SM, Lee KH, Bieber T. Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review. EBioMedicine. 2024;103:105121. doi: 10.1016/j.ebiom.2024.105121 EDN: UNWODDOhya Y. Prevention of atopic dermatitis: what are we missing? Allergy Asthma Immunol Res. 2025;17(4):433–446. doi: 10.4168/aair.2025.17.4.433 EDN: BNAMUBWollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema — part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(10):1904–1926. doi: 10.1111/jdv.18429 EDN: MLXMVLSaeki H, Ohya Y, Furuta J, et al; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021, The Japanese Society of Allergology, The Japanese Dermatology Association. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448–458. doi: 10.1016/j.alit.2022.06.009 EDN: EHBJDEEichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi: 10.1016/j.jaad.2014.03.023Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I — systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: 10.1111/jdv.18345 EDN: HYTUSXSidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi: 10.1016/j.jaad.2014.03.030Kim DH, Choi E, Lee JS, et al. House dust mite allergen regulates constitutive apoptosis of normal and asthmatic neutrophils via Toll-like receptor 4. PLoS One. 2015;10(5):e0125983. doi: 10.1371/journal.pone.0125983Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. doi: 10.1016/j.jaci.2017.04.004Huang HJ, Sarzsinszky E, Vrtala S. House dust mite allergy: the importance of house dust mite allergens for diagnosis and immunotherapy. Mol Immunol. 2023;158:54–67. doi: 10.1016/j.molimm.2023.04.008 EDN: GEGLFVItamura M, Sawada Y. Involvement of atopic dermatitis in the development of systemic inflammatory diseases. Int J Mol Sci. 2022;23(21):13445. doi: 10.3390/ijms232113445 EDN: EDYYBUElisyutina OG, Litovkina AO, Smolnikov EV, Fedenko ES. The experience with subcutaneous allergen-specific immunotherapy with pollen allergens in patients with atopic dermatitis. Russian Journal of Allergy. 2024;21(1):17–28. (In Russ.) doi: 10.36691/RJA16911 EDN: LTBGFDBumbacea RS, Corcea SL, Ali S, et al. Mite allergy and atopic dermatitis: is there a clear link? (Review). Exp Ther Med. 2020;20(6):3554–3560. doi: 10.3892/etm.2020.9120 EDN: HIXQQKCompalati E, Rogkakou A, Passalacqua G, Canonica GW. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr Opin Allergy Clin Immunol. 2012;12(4):427–433. doi: 10.1097/ACI.0b013e328354e540Guo BC, Wu KH, Chen CY, et al. Advancements in allergen immunotherapy for the treatment of atopic dermatitis. Int J Mol Sci. 2024;25(2):1316. doi: 10.3390/ijms25021316 EDN: PGQWPUShtyrbul OV, Dvornikov AS, Khaitov MR, et al. Molecular allergodiagnostics capabilities in determining the indications for allergen-specific immunotherapy with house dust mites allergen and its effectiveness in atopic dermatitis patients. Russian Journal of Allergy. 2020;17(3):82–92. (In Russ.) doi: 10.36691/RJA1389 EDN: GHNUIZCalderón MA, Linneberg A, Kleine-Tebbe J, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136(1):38–48. doi: 10.1016/j.jaci.2014.10.012 EDN: URSUSVKita H. How are airborne allergens remembered by the immune system? J Allergy Clin Immunol. 2022;149(6):1940–1942. doi: 10.1016/j.jaci.2022.02.014 EDN: DDYOZNBarry J, Loh Z, Collison A, et al. Absence of Toll-IL-1 receptor 8/single immunoglobulin IL-1 receptor-related molecule reduces house dust mite-induced allergic airway inflammation in mice. Am J Respir Cell Mol Biol. 2013;49(3):481–490. doi: 10.1165/rcmb.2012-0425OCVrtala S. Allergens from house dust and storage mites. Allergo J Int. 2022;31(5):267–271. doi: 10.1007/s40629-022-00226-5 EDN: MATWAYSmolnikov EV, Litovkina AO, Kolykhalova KI, et al. The role of atopy patch test with aeroallergens in allergic diseases diagnostics. Russian Journal of Allergy. 2021;17(4):30–37. (In Russ.) doi: 10.36691/RJA1355 EDN: HXCCPORing J, Kunz B, Bieber T, et al. The “atopy patch test” with aeroallergens in atopic eczema (Abstr.). J Allergy Clin Immunol. 1989;82(1):195.Gutermuth J, Grosber M, Pfaar O, et al. One hundred and eleven years of allergen-immunotherapy: a long and successful history of the only available disease-modifier in allergic diseases. Allergol Select. 2022;6:248–258. doi: 10.5414/ALX02330E EDN: KYRCUOCox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(Suppl 1):S1–55. doi: 10.1016/j.jaci.2010.09.034Bumbacea RS, Boustani R, Panaitescu C, et al. Mechanisms of allergen immunotherapy supporting its disease-modifying effect. Immunotherapy. 2022;14(8):627–638. doi: 10.2217/imt-2021-0325 EDN: JIIXDVYepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, et al. Allergen immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2023;151(1):147–158. doi: 10.1016/j.jaci.2022.09.020 EDN: LCXFIQ.Cox L. Allergen immunotherapy: immunomodulatory treatment for allergic diseases. Expert Rev Clin Immunol. 2006;2(4):533–546. doi: 10.1586/1744666X.2.4.533Akdis CA, Akdis M. Advances in allergen immunotherapy: aiming for complete tolerance to allergens. Sci Transl Med. 2015;7(280):280ps6. doi: 10.1126/scitranslmed.aaa7390Han H, Roan F, Ziegler SF. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017;278(1):116–130. doi: 10.1111/imr.12546 EDN: YFHASQKaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy. 1974;32(6):321–330.Mastrandrea F. Immunotherapy in atopic dermatitis. Expert Opin Investig Drugs. 2001;10(1):49–63. doi: 10.1517/13543784.10.1.49Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978;2(8096):912–915. doi: 10.1016/S0140-6736(78)91630-6Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120(1):164–170. doi: 10.1016/j.jaci.2007.04.008 EDN: MAGVRDCaminiti L, Panasiti I, Landi M, et al. Allergen immunotherapy in atopic dermatitis: light and shadow in children. Pediatr Allergy Immunol. 2020;31 (Suppl 26):46–48. doi: 10.1111/pai.13390 EDN: PRBIYWBae JM, Choi YY, Park CO, et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110–117. doi: 10.1016/j.jaci.2013.02.044Traidl S, Werfel T. Allergenimmuntherapie bei atopischer Dermatitis. Hautarzt. 2021;72(12):1103–1112. (In German) doi: 10.1007/s00105-021-04909-y EDN: ANFPOAShamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 2017;140(6):1485–1498. doi: 10.1016/j.jaci.2017.10.010Golebski K, Layhadi JA, Sahiner U, et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity. 2021;54(2):291–307.e7. doi: 10.1016/j.immuni.2020.12.013 EDN: GNGHNUWerfel T, Heratizadeh A, Niebuhr M, et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol. 2015;136(1):96–103.e9. doi: 10.1016/j.jaci.2015.04.015Kim J, Boo J, Jang H, et al. Combined dupilumab and allergen-specific immunotherapy in severe refractory atopic dermatitis. Allergy Asthma Immunol Res. 2024;16(6):682–689. doi: 10.4168/aair.2024.16.6.682 EDN: HFZFOHLiu J, Yang L, Xu Q, et al. Allergen immunotherapy and dupilumab in atopic dermatitis: clinical efficacy and disparities in immunological indicators. World Allergy Organ J. 2025;18(3):101043. doi: 10.1016/j.waojou.2025.101043 EDN: RUXOMCBogacz-Piaseczyńska A, Bożek A, Krupka-Olek M, et al. Dupilumab and house dust mite immunotherapy in patients with atopic dermatitis: a preliminary study. Vaccines (Basel). 2024;12(9):1046. doi: 10.3390/vaccines12091046 EDN: TRGHLNЕлисютина ОГ, Феденко ЕС. Место специфической иммунотерапии в лечении больных атопическим дерматитом, осложненным рецидивирующей пиодермией. Физиология и патология иммунной системы. 2006;8:15–20.Elisyutina O, Fedenko E. Specific immunotherapy in atopic dermatitis with staphylococcal and house dust mite allergovaccines. Allergy. 2007;62(Suppl 83):92.Slavyanskaya TA, Derkach VV, Sepiashvili RI. Modern approaches to specific immunotherapy in atopic dermatitis children. Russian Journal of Allergy. 2015;12(5):31–38. (In Russ.) doi: 10.36691/RJA431 EDN: VLMLGX